Skip to main content

Table 5 Scenario analysis cost and outcomes when considering direct effects only

From: Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

Outcome

PCV13

PCV10

Difference (PCV13 – PCV10)

Total life-years

605,587,157

605,586,870

287.45

  Total QALYs

543,278,132

543,264,303

257.70

Annual number of cases

  Myringotomy

1,906

1,918

−11.0

  Neurological impairment

35.7

35.8

−0.1

  Hearing loss

66.3

66.5

−0.2

  Death

10,466.50

10,480.47

−14.0

  Annual direct medical costs

$1,312,418,621

$1,318,177,638

–$5,759,017

Cost per QALY

PCV13 dominates PCV10

  1. PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine; QALY quality-adjusted life-year.